Analyst Ratings for Clinical Data (CLDA)
Overall Rating:
NEUTRAL
Rating Trend:
=
Avg. $ Target:
N/A
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/24/2011 | BMO Capital | Downgrade | Market Perform (N/A) |
N/A (N/A) |
30.95 | 30.95 | 0% | Details |
| 2/23/2011 | Wedbush | Downgrade | Neutral (N/A) |
N/A (N/A) |
31.21 | 30.95 | -0.83% | Details |
| 2/22/2011 | McNicoll Lewis & Vlak | Downgrade | Hold (N/A) |
N/A (N/A) |
33.90 | 30.95 | -8.7% | Details |
| 2/22/2011 | Rodman & Renshaw | Downgrade | Market Perform (N/A) |
N/A (N/A) |
31.01 | 30.95 | -0.19% | Details |
| 2/22/2011 | Piper Jaffray | Downgrade | Neutral (N/A) |
N/A (N/A) |
31.01 | 30.95 | -0.19% | Details |
| 2/22/2011 | Roth Capital | Downgrade | Neutral (N/A) |
N/A (N/A) |
31.05 | 30.95 | -0.32% | Details |
CLDA Ratings News
- BMO Capital Downgrades Clinical Data (CLDA) to Market Perform
- Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Clinical Data Deal Brings Solid SSRI Entrant Viibryd Though “Too Little Too Late” & Undifferentiated Profile Concerns
- Wedbush Downgrades Clinical Data (CLDA) to Neutral; Forest Buying CLDA for $30 Plus CVR,
- See More
